首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
【24h】

Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.

机译:5-氟尿嘧啶在大肠癌中临床疗效的潜在药物基因组学标志物的鉴定。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Although adjuvant chemotherapy has significantly increased overall survival in resected Stage III colorectal cancer, disease recurrence is still high (30-40%). 20-25% of Stage II patients also develop recurrent disease. Thus, high-risk patients may benefit from chemotherapy. As patient response to standard chemotherapy varies, the study of molecular differences in the expression of pharmacologically relevant genes may help clinicians to understand variability and tailor therapy. The expression of 5-fluorouracil (5-FU) pathway genes in tumors from 53 Stages II-III colorectal cancer patients who underwent 5-FU adjuvant chemotherapy was investigated by reverse transcription quantitative real-time polymerase chain reaction. Patients were dichotomized into high- and low-mRNA expression level groups using median values of gene mRNA levels. Then, a threshold analysis to identify a cut-off distinguishing recurrent- or nonrecurrent-disease was used. A high degree of interpatient variation in relative tumor expression of study genes was observed. Multiple gene correlations were found, which suggest possible coregulation mechanisms. No statistically significant relationship between experimental data and baseline clinical/pathological characteristics or clinical outcome was observed using gene expression median values. Threshold analysis indicated significant inverse relationships between deoxyuridine triphosphatase (DUT), ferrodoxin reductase (FDXR) or tumor protein p53 (TP53) and disease-free survival (DFS) in the entire case series and between DUT or NM23-H1 and DFS in Stage III patients: higher gene expression was associated with shorter DFS. This study provides data on relationships between expression of 5-FU pathway genes and clinical outcome of colorectal cancer patients undergoing 5-FU adjuvant chemotherapy and underscores the predictive role of specific genes. Validation in an independent case series is warranted.
机译:尽管辅助化疗在已切除的III期大肠癌中显着提高了总生存率,但疾病复发率仍然很高(30-40%)。 II期患者中有20-25%也会复发。因此,高危患者可能会从化疗中受益。随着患者对标准化疗的反应发生变化,对药理相关基因表达的分子差异的研究可能有助于临床医生了解变异性并调整治疗方案。通过逆转录定量实时聚合酶链反应研究了5-氟尿嘧啶(5-FU)通路基因在接受5-FU辅助化疗的53例II-III期大肠癌患者的肿瘤中的表达。使用基因mRNA水平的中值将患者分为高和低mRNA表达水平组。然后,使用阈值分析来确定区分复发性或非复发性疾病的临界值。观察到患者间研究基因相对肿瘤表达的高度差异。发现了多个基因相关性,这提示可能的调控机制。使用基因表达中值未观察到实验数据与基线临床/病理特征或临床结果之间的统计学显着性关系。阈值分析表明,在整个病例系列中以及第三阶段的DUT或NM23-H1与DFS之间,脱氧尿苷三磷酸酶(DUT),铁氧还蛋白还原酶(FDXR)或肿瘤蛋白p53(TP53)与无病生存率(DFS)之间存在显着的负相关。患者:较高的基因表达与较短的DFS相关。这项研究提供了5-FU通路基因表达与接受5-FU辅助化疗的结直肠癌患者临床结局之间关系的数据,并强调了特定基因的预测作用。有必要在独立的案例系列中进行验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号